The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization in the European Union for Eli Lilly’s Foundayo ...
The FDA approved Enspryng (satralizumab) on Oct. 16 for adults with thyroid eye disease (TED). 1 Roche describes the ...
Logan Melchione shares how ClaimGuardRx gives account teams a fast, conversational way to tackle diversion and fraud together, and what that means for clients and patients. Biopharma manufacturers are ...
After months of prodding, the European Medicines Agency (EMA) and member states of the European Union have begun taking ...
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
President Trump’s Most-Favored Nation (MFN) initiative continues to impact the industry. Most recently, the deadline passed ...
Pharmaceutical Executive spoke with Marc Wagner, an FDA and life sciences attorney at Fox Rothschild, about the manufacturing ...
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization. There is a conversation happening in boardrooms and brand planning cycles across the pharmaceutical industry ...
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human. Consider a hypothetical launch review, six ...
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results